Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296320 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of MEDI4893
A Phase 2 study of Staphylococcus Aureus Pneumonia, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
- 20
- Study locations
NCT02296320: Completed Phase 2 study of Staphylococcus Aureus Pneumonia, sponsored by MedImmune.
NCT02296320 is a Phase 2 study of Staphylococcus Aureus Pneumonia that has completed, run by MedImmune. The registered enrollment target is 213 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296320, a Phase 2 study of Staphylococcus Aureus Pneumonia, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
- 20
- Study locations
Study Summary
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Primary Outcome
The EAC S aureus pneumonia was based on clinical, radiographic, and microbiologic criteria. Clinical criteria: 1 major criteria (PaO2/FiO2 ratio \< 240 mmHg maintained for at least 4 hours or decrease in PaO2/FiO2 by \>= 50 mmHg maintained for at least 4 hrs or a need to initiate non-invasive mechanical ventilation or re-initiate invasive mechanical ventilation because of respiratory failure or worsening of respiratory status); and at least 2 of minor criteria (systemic signs of infection, produ
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MEDI4893
Study Locations (20)
Other
- Research Site - Arlon
- Research Site - Brussels
- Research Site - La Louvière
- Research Site - Lodelinsart
- Research Site - Yvoir
- Research Site - Brno
- Research Site - Děčín
- Research Site - Kyjov
- Research Site - Prague
- Research Site - Teplice
- Research Site - Angers
- Research Site - Clermont-Ferrand
- Research Site - Garches
- Research Site - Grenoble
- Research Site - Le Chesnay
- Research Site - Lille
- Research Site - Limoges
- Research Site - Lyon
Georgia
- Research Site - Atlanta
Michigan
- Research Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2014-10-10 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 2 |
What the finished NCT02296320 record still lists
NCT02296320 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Staphylococcus Aureus Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02296320 names 20 study sites across 3 states, led by Other, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT02296320 about?
NCT02296320 is a clinical study titled "Study of the Efficacy and Safety of MEDI4893". Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
What is the current status of trial NCT02296320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2014-10-10. Estimated completion is 2018-10-02.
What conditions does trial NCT02296320 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Pneumonia.
What interventions are being tested in trial NCT02296320?
The interventions under investigation include: Placebo (OTHER), MEDI4893 (DRUG).
Who is sponsoring clinical trial NCT02296320?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296320 being conducted?
This trial has 20 study locations across Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02296320's enrollment target sits among peer trials
213 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI